Markets:

Overview

News

Currencies

International

Treasuries

Roche Holding Div RTS (OP:RHHVF)

411.56 +6.56 (+1.62%)

Streaming Delayed Price Updated: 12:41 PM EDT, Jun 16, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Roche Holding Div RTS

< Previous 1 2 3 4 5 6 7 Next >

Roche Puts Alzheimer's Candidate, Gantenerumab In Spotlight; In Dialogue with FDA: Reuters ↗

July 22, 2021

Roche Holding AG (OTC: RHHBY) is reportedly talking to the FDA about its Alzheimer’s disease drug candidate, gantenerumab. CEO Severin Schwan declined...

Via Benzinga

Rebound In COVID-19 Tests Lift Roche's Half-Year Sales, Oncology Still Hit By Biosimilars, Pandemic ↗

July 22, 2021

Roche Holding AG's (OTC: RHHBY) 1H 2021 sales increased by 8% Y/Y at constant exchange rates (CER) to CHF 30.7 billion as peak demand for COVID-19 tests helped...

Via Benzinga

Spark Therapeutics' Hemophilia Gene Therapy Achieve Stable, Durable FVIII Expression ↗

July 21, 2021

Spark Therapeutics, a unit of Roche Holdings AG (OTC: RHHBY), has announced updated data from the ongoing Phase 1/2 trial of SPK-8011 gene therapy in...

Via Benzinga

AbbVie - Roche's Venclexta Receives Breakthrough Therapy Tag In High-Risk Myelodysplastic Syndromes ↗

July 21, 2021

The FDA has granted Breakthrough Therapy Designation (BTD) to Venclexta (venetoclax) combined with azacitidine for the potential treatment of adult patients with...

Via Benzinga

Roche Unveils New Hemlibra Data Reinforcing Safety Profile In Hemophilia A ↗

July 19, 2021

According to Roche Holding AG's (OTC: RHHBY) Genentech division, new data from a phase 3b study reinforces the safety profile of blockbuster hemophilia A...

Via Benzinga

Celldex Stock Surges As It Touts Early-Stage Skin Disease Study Win For CDX-0159 ↗

July 12, 2021

Celldex Therapeutics Inc (NASDAQ: CLDX) got a boost Friday with a data readout from Phase 1b trial of CDX-0159 in patients with antihistamine refractory cold...

Via Benzinga

WHO Recommends IL-6 Drugs From Sanofi, Roche For Critically-Ill COVID-19 Patients ↗

July 07, 2021

The World Health Organization (WHO) has endorsed Interleukin-6 (IL-6) receptor antagonists combined with corticosteroids to treat severe COVID-19 cases. Patients...

Via Benzinga

Atea Pharma's AT-527 Rapidly Reduces Viral Load Levels In Hospitalized COVID-19 Patients ↗

June 30, 2021

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has announced positive interim results from a Phase 2 study evaluating AT-527 in hospitalized patients with mild-to-...

Via Benzinga

Novartis Claims It Overpaid Genentech $210M In Patent Licensing Pact ↗

June 29, 2021

Novartis AG (NYSE: NVS) said it dutifully paid millions to Genentech as part of a patent licensing deal dated back to 2005. But now, Novartis discovered it...

Via Benzinga

Topics Intellectual Property

Exelixis Shares Drop On Mixed Results For Cabometyx Combo In Early Liver Cancer ↗

June 28, 2021

Exelixis Inc (NASDAQ: EXEL) and Ipsen (OTC: IPSEY) have announced mixed interim results from the COSMIC-312 Phase 3 trial evaluating cabozantinib (...

Via Benzinga

Roche's Enspryng Wins European Approval For Spinal Cord, Optic Nerve Inflammation Disorder ↗

June 28, 2021

The European Commission has approved Roche Holding AG's (OTC: RHHBY) injectable Enspryng for adults and adolescents with neuromyelitis optica spectrum disorder...

Via Benzinga

FDA Gives Emergency Use Nod For Roche's Arthritis Drug Against Severe COVID-19 ↗

June 25, 2021

The

Via Benzinga

Roche's Alzheimer's Antibody Reduces Associated Biomarkers In Subset Of AD Patients, Study Shows ↗

June 22, 2021

Experimental anti-amyloid antibodies from Eli Lilly & Co (NYSE: LLY) and Roche Holding AG's (OTC: RHHBY) failed to improve symptoms of Alzheimer's...

Via Benzinga

Roche's New COVID-19 Point Of Care Test Scores FDA Emergency Use Nod ↗

June 18, 2021

The FDA has granted Emergency Use Authorization (EUA) to Roche Holding AG's (OTC: RHHBY) Cobas SARS-CoV-2 Nucleic acid test for use on the Cobas Liat...

Via Benzinga

Amneal's Avastin-Referred Biosimilar Under FDA Review For Colorectal Cancer ↗

June 17, 2021

The FDA has accepted for review Amneal Pharmaceuticals Inc's (NYSE: AMRX) marketing application seeking approval for Bevacizumab, under Section 351(k) pathway...

Via Benzinga

Synlogic, Roche Ink Research Pact For Inflammatory Bowel Disease Therapy ↗

June 17, 2021

Synlogic Inc (NASDAQ: SYBX) has entered into a research collaboration agreement with Roche Holding AG (OTC: RHHBY) for the discovery of Synthetic Biotic...

Via Benzinga

Atea Pharma Secures AT-527-Related Milestone Payment Of $50M From Roche ↗

June 16, 2021

Atea Pharmaceuticals Inc (NASDAQ: AVIR) has achieved a development milestone associated with AT-527 and expects to receive a related payment under its license...

Via Benzinga

JNJ's Imbruvica, AbbVie's Venclexta Combo Achieves Progression-Free Survival Of 78.4% Versus Gazyva-Chemo Cocktail In Leukemia Patients ↗

June 14, 2021

A combination of Johnson & Johnson’s (NYSE: JNJ) Imbruvica and AbbVie Inc (NYSE: ABBV) - Roche Holding AG’s (OTC: RHHBY) Venclexta/...

Via Benzinga

AbbVie-Roche's Venclexta Shows Progression-Free Survival Of 74% In CLL Patients After Three Years Treatment ↗

June 11, 2021

Genentech, a unit of Roche Holdings AG (OTC: RHHBY), and its collaborating partner AbbVie Inc (NYSE: ABBV) have announced long-term follow-up data ...

Via Benzinga

Argenx Regains Global Rights from Johnson & Johnson to Blood Cancer Candidate Cusatuzumab ↗

June 07, 2021

Johnson & Johnson (NYSE: JNJ) has walked away from a $1.6 billion blood cancer candidate deal with Argenx SE (NASDAQ: ARGX) for the CD70-targeting...

Via Benzinga

Surface Oncology, Roche Team Up to Develop SRF388 Combo Therapy for Liver Cancer ↗

June 04, 2021

Surface Oncology (NASDAQ: SURF) has entered into a clinical trial collaboration with Roche Holdings AG (OTC: RHHBY) to evaluate former's SRF388, anti...

Via Benzinga

Biogen, Bio-Thera's Biosimilar Referencing Tocilizumab Meets Primary Endpoints In Late-Stage Study ↗

June 01, 2021

Biogen Inc (NASDAQ: BIIB) and China's Bio-Thera Solutions Ltd have announced results from the Phase 3 study of BAT1806, a proposed biosimilar referencing...

Via Benzinga

AbbVie-Roche Win European Approval for Venclyxto in Newly Diagnosed Acute Myeloid Leukemia ↗

May 25, 2021

The European Commission has approved AbbVie Inc's (NYSE: ABBV) Venclyxto (venetoclax) for the treatment of adult patients with newly diagnosed acute myeloid...

Via Benzinga

Pieris Stock Surges on Development Pact with Genentech for Respiratory, Ophthalmology Settings ↗

May 25, 2021

Pieris Pharmaceuticals Inc (NASDAQ: PIRS) has entered into a multi-program research collaboration and license agreement with Genentech, a unit of ...

Via Benzinga

Exelixis' Cabometyx, Roche's Tecentriq Combo Achieves 27% ORR in High-Risk Prostate Cancer Patients ↗

May 25, 2021

Exelixis Inc (NASDAQ: EXEL) has announced results from cohort 6 of the COSMIC-021 Phase 1b trial evaluating Cabometyx (cabozantinib) in combination...

Via Benzinga

I-Mab Showcases Early Data On Uliledlimab/Atezolizumab Combo In Advanced Cancer Settings ↗

May 20, 2021

I-Mab (NASDAQ: IMAB) unveiled early results from Phase 1 study evaluating uliledlimab in combination with Roche Holdings AG’s (OTC: RHHBY)...

Via Benzinga

Roche's Cobas COVID Test Scores EUA For Asymptomatic People ↗

May 18, 2021

Roche Holdings AG’s (OTC: RHHBY) Cobas SARS-CoV-2 Test has received U.S. authorization for testing individuals without symptoms or reasons to suspect a COVID...

Via Benzinga

Prothena Receives $60M Milestone Payment After Parkinson's Candidate Moves Forward In Mid-Stage Study With Dosing ↗

May 11, 2021

Prothena Corporation plc (NASDAQ: PRTA) has dosed the first patient in the Phase 2b PADOVA study evaluating prasinezumab in patients with early...

Via Benzinga

India Gives Emergency Use Nod To Roche-Regeneron's COVID-19 Antibody Cocktail ↗

May 05, 2021

Roche Holdings AG (OTCMKTS: RHHBY) has received Emergency Use Authorization in India for its investigational antibody cocktail (casirivimab and imdevimab) for...

Via Benzinga

Oncologic Drugs Adcomm Backs Merck's Keytruda, Roche's Tecentriq Accelerated Approvals In Bladder Cancer ↗

April 29, 2021

The FDA’s Oncologic Drugs Advisory Committee voted 5-3 in favor of keeping Merck & Co’s (NYSE: MRK) Keytruda (pembrolizumab) accelerated approval...

Via Benzinga

< Previous 1 2 3 4 5 6 7 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.